MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
1.110
0.000
0.00%
After Hours: 1.080 -0.03 -2.70% 19:19 06/21 EDT
OPEN
1.120
PREV CLOSE
1.110
HIGH
1.128
LOW
1.080
VOLUME
146.73K
TURNOVER
0
52 WEEK HIGH
3.110
52 WEEK LOW
0.9451
MARKET CAP
99.99M
P/E (TTM)
-0.6037
1D
5D
1M
3M
1Y
5Y
Immunic, Inc.'s (NASDAQ:IMUX) latest 15% decline adds to one-year losses, hedge funds investors may consider drastic measures
Hedge funds own 39% of Immunic, Inc. (NASDAQ:IMUX) The top 7 shareholders own 51% of the company. The company has a market cap of US$103m. Hedge funds investors were most impacted by the recent drop in Immunic's share price. High institutional ownership implies the company's stock price is sensitive to their trading actions. Immunic is owned by a group of hedge funds with a 39% stake in the firm. It's worth looking at the diversity of its shareholders to see how the company operates.
Simply Wall St · 3d ago
Weekly Report: what happened at IMUX last week (0610-0614)?
Weekly Report · 5d ago
IMMUNIC-FILES PROSPECTUS SUPPLEMENT FOR SALE $80.0 MLN OF SHARES OF COMMON STOCK, MAY OFFER & SELL FROM TIME TO TIME THROUGH LEERINK PARTNERS
Reuters · 06/10 20:15
IMMUNIC INC -HAD PREVIOUSLY ENTERED INTO SALES AGREEMENT WITH LEERINK PARTNERS DATED MAY 2, 2022 RELATING TO SHARES OF COMMON STOCK
Reuters · 06/10 20:15
Weekly Report: what happened at IMUX last week (0603-0607)?
Weekly Report · 06/10 09:18
Immunic Stock (IMUX): Striving to Develop Innovative Therapies
TipRanks · 06/10 07:33
Weekly Report: what happened at IMUX last week (0527-0531)?
Weekly Report · 06/03 09:19
Weekly Report: what happened at IMUX last week (0520-0524)?
Weekly Report · 05/27 09:19
More
About IMUX
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.